Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications
Yes, you can combine these two treatments
It targets three key receptors simultaneously glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Reported side effects of BPC-157 in clinical observation (not formal trials) include injection site irritation, mild nausea, dizziness, and transient headache
Product concentration, delivery method, treatment goal and individual health risks can also change how dosage questions should be evaluated
If your concern is gut health, oral capsules may be the better fit